NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Zentalis Pharmaceuticals reported its first quarter 2025 financial results and operational progress, highlighting the advancement of its lead product candidate, azenosertib.
Zentalis Pharmaceuticals reported a net loss of $48.3 million for the first quarter of 2025, a significant decrease from the net income of $10.1 million in the same period last year, primarily due to the absence of license revenue and higher operating expenses including restructuring costs. The company ended the quarter with $332.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2027. Key operational progress included the first patient dosed in Part 2a of the Phase 2 DENALI clinical trial for azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer.
- Net loss for Q1 2025 was $48.3 million, compared to net income of $10.1 million in Q1 2024.
- Cash, cash equivalents, and marketable securities totaled $332.5 million as of March 31, 2025, providing an operational runway into late 2027.
- Research and development expenses decreased to $27.2 million in Q1 2025 from $49.6 million in Q1 2024.
- The first patient was dosed in Part 2a of the Phase 2 DENALI clinical trial for azenosertib in Cyclin E1+ platinum-resistant ovarian cancer.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$0
Forward guidance
Zentalis Pharmaceuticals anticipates topline data from the DENALI Part 2 trial by year end 2026, which has the potential to support an accelerated approval for azenosertib in platinum-resistant ovarian cancer. The company's current cash position is expected to fund operations into late 2027. Zentalis plans to participate in several upcoming scientific and investor conferences.
Tailwinds
- Anticipated topline data from DENALI Part 2 by year end 2026.
- Potential for DENALI Part 2 data to support accelerated approval, subject to FDA feedback.
- Existing cash, cash equivalents, and marketable securities expected to fund operations into late 2027.
- First patient dosed in DENALI Part 2a clinical trial.
- Planned participation in multiple scientific and investor conferences.
Headwinds
- Topline data from DENALI Part 2 is not expected until year end 2026.
- Accelerated approval is subject to FDA review and feedback.
- Clinical trial outcomes are inherently uncertain.
- The company has a limited operating history and has incurred significant losses.
- Need for additional funding may arise in the future.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-1.7%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+2.4%
Avg return
30 days after
58%
14 / 24 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -1.7% | — | |
| Q4 2025 | +3.1% | -3.7% | +49.1% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro